An Open Letter to CVBT Leadership
Dear CVBT Leadership,
With the shareholders meeting a little over two weeks away, a number of shareholders have been frustrated by past Internet shareholder meetings because none of the very reasonable questions any of us have asked have ever been answered. These Internet meetings limit communication and prevent shareholders from having our voices publicly heard. CVBT self-selects which questions to answer, yet no one gets to hear the questions that were asked in the first place.
As CVBT’s leadership reads this message board, I am going to publicly post three very reasonable questions we will ask at the shareholders meeting in two weeks. Hopefully you will answer them, but if not, at least everyone will know they were questions asked of CVBT's leadership which the leadership refused to answer:
1. Since 2016 through today, how much in total equity has CVBT raised? At what price(s) per share? Of the total amount raised, how much came from investors others than CVBT’s CEO Calvin Wallen?
2. At last year’s shareholder meeting, CVBT stated that the Phase II heart clinical trial will be starting in 2019, and the peripheral artery disease trial will be starting in late 2019 or 2020. Yes or no, does CVBT have all the required funding in-hand TODAY to conduct these trials and run the company during this period? If the answer is no, how much in funding is still needed?
3. There are rumors on the message board for many months now that CVBT will be going public again “soon.” Yes or no, will CVBT be going public in 2019?
Thank you!
AI
